[ad_1] CHICAGO — The monoclonal antibody ustekinumab (Stelara) showed sustained clinical benefits for systemic lupus erythematosus (SLE) through 1 year and may offer a new therapeutic option, according to a researcher here. …
Read More »ACR: IL-12/23 Blocker Offers Long-Term Benefits in SLE
